aTyr Pharma, Inc. (ATYR) AI Stock Analysis

aTyr Pharma, Inc. is a biotherapeutics company based in San Diego, California, dedicated to discovering and developing medicines targeting novel immunological pathways. Its lead therapeutic candidate, efzofitimod, is in Phase III clinical trials for pulmonary sarcoidosis and Phase 1b/2a trials for interstitial lung diseases, including chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also advancing preclinical candidates ATYR0101 for fibrosis and ATYR0750 for liver disorders. Additionally, aTyr Pharma maintains a strategic partnership with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for interstitial lung diseases in Japan.

Revenue dropped from $10.5M in FY2020 and $10.4M in FY2022 to $353,000 in FY2023, $235,000 in FY2024, and $190,000 in FY2025, representing a 5-year revenue CAGR of -14.8% from FY2019 to FY2025. Annual net income was -$16.2M in FY2020, -$45.3M in FY2022, -$50.4M in FY2023, -$64.0M in FY2024, and -$74.1M in FY2025. Over the same period, R&D expenses increased from $17.3M in FY2020 to $60.2M in FY2025. Operating margin in FY2025 was -40856.3%, and gross margin was -717.4%. For the trailing twelve months ending June 30, 2026, revenue stood at $190,000 with an operating margin of -33609.5% and diluted EPS of -$0.62.

As of June 30, 2026, aTyr Pharma held $57.4M in cash and short-term investments against $11.3M in total debt, leaving net cash of $46.1M. Shareholders' equity was $48.8M and total assets were $69.8M, supported by a current ratio of 5.12 and a debt-to-equity ratio of 0.23. In FY2025, operating cash flow was -$62.0M and free cash flow was -$62.1M, with capital expenditures of $77,000. Over the past five years, the company's share count increased 252.9%.

At a last close of $0.17 on October 16, 2026, aTyr Pharma had a market capitalization of $17.1M and an enterprise value of -$9.4M. Its price-to-sales ratio was 89.8x, compared to the median of 4.1x for its US-listed Healthcare peers, while its price-to-book ratio stood at 0.8x. Over the past year, the stock fell 82.6% compared to a 16.8% return for the S&P 500 (SPY). Over five years, the stock fell 98.0%, trailing the 83.0% return of the S&P 500.

Among Wall Street analysts, aTyr Pharma has 2 Strong Buy, 2 Buy, and 5 Hold ratings, with 0 Sell or Strong Sell ratings. The mean price target is $2.86, representing a 1542.0% premium over the last close of $0.17. For the fiscal year ending December 31, 2026, analysts estimate EPS of -$0.41 and revenue of $0. For the following fiscal year, 8 analysts estimate EPS of -$0.44 and revenue of $0. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of aTyr Pharma, Inc. (ATYR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ATYR income statement, ATYR balance sheet, ATYR key metrics, ATYR analyst forecast, ATYR chart. See the ATYR stock overview for the latest quote and news.